Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages 556-565

  Lin, Jessica J ^a,b   Cardarella, Stephanie ^a,c   Lydon, Christine A ^a   Dahlberg, Suzanne E ^a   Jackman, David M ^a,b,d   Jänne, Pasi A ^a,b,d   Johnson, Bruce E ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

EGFR; Long term survival; Non small cell lung cancer; TKI

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; EGFR GENE; EXON; FEMALE; GENE DELETION; HUMAN; LIVER METASTASIS; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTANT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEPTOR GENE; TREATMENT OUTCOME; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; EPIDEMIOLOGY; GENETICS; LUNG NEOPLASMS; MASSACHUSETTS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASSACHUSETTS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84962791859     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.12.103     Document Type: Article

References (50)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
7. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
8. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-128.
9. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385: 977-1010.
10. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. Based on November 2013 SEER data submission, posted to the SEER website, April 2014. Bethesda, MD, National Cancer Institute. http://seer.cancer.gov/csr/1975-2011/. Accessed November 1, 2015.
11. Van Damme V, Govaerts E, Nackaerts K, et al. Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. Lung Cancer. 2013;79:73-76.
12. Ozkaya S, Findik S, Dirican A, et al. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinor-elbine or gemcitabine. Exp Ther Med. 2012;4:1035-1038.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
14. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J Clin Oncol. 2003;21:2237-2246.
15. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290: 2149-2158.
16. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
17. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
18. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
19. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
20. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
22. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
23. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908-3914.
24. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839-844.
25. Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406-4414.
26. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873-5882.
27. Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008;14:7060-7067.
28. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357-360.
29. Park K, Ahn M, Yu C, et al. ASPIRATION: first-line erlo-tinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mutθ) NSCLC. Ann Oncol. 2014;25:iv426-iv470.
30. Lo PC, Dahlberg SE, Nishino M, et al. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015;121:2570-2577.
31. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:433-440.
32. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-2874.
33. Nishino K, Imamura F, Morita S, et al. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer. 2013;82:299-304.
34. Okamoto T, Maruyama R, Shoji F, et al. Long-term survivors in stage IV non-small cell lung cancer. Lung cancer. 2005;47:85-91.
35. Satoh H, Ishikawa H, Ohara G, et al. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007;27:4457-4460.
36. Giroux Leprieur E, Lavole A, Ruppert AM, et al. Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology. 2012;17:134-142.
37. Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer. 2010;67:120-123.
38. Chen YZ, Feng XB, Li ZD, et al. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and Western medicine. Chin J Integr Med. 2014;20: 179-183.
39. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24: 54-59.
40. Yoshioka H, Mitsudomi T, Morita S, et al. Final overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus doce-taxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) [abstract] J Clin Oncol. 2014;32(suppl):8117.
41. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105:595-605.
42. Cardarella S, Johnson BE. Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts. J Natl Cancer Inst. 2013;105:589-590.
43. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16: 141-151.
44. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.
45. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15:213-222.
46. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97:1185-1194.
47. Park JH, Kim TM, Keam B, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin Lung Cancer. 2013;14:383-389.
48. Lee JY, Lim SH, Kim M, et al. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Cancer Chemother Pharmacol. 2014;73:1063-1070.
49. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23:6207-6219.
50. Berger LA, Riesenberg H, Bokemeyer C, et al. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 2013;80:242-248.